Axel Hauschild, MD, PhD | Authors


Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma

June 23, 2020

Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.